Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains

Alzheimer's Research and Therapy

Volumn 4, Issue 3, 2012, Pages

  Moore, Brenda D ^a   Chakrabarty, Paramita ^a   Levites, Yona ^a   Kukar, Tom L ^b   Baine, Ann Marie ^c   Moroni, Tina ^c   Ladd, Thomas B ^a   Das, Pritam ^c   Dickson, Dennis W ^c   Golde, Todd E ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-18]; AMYLOID BETA PROTEIN[1-22]; AMYLOID BETA PROTEIN[1-26]; AMYLOID BETA PROTEIN[1-27]; AMYLOID BETA PROTEIN[1-29]; AMYLOID BETA PROTEIN[1-31]; AMYLOID BETA PROTEIN[1-36]; AMYLOID BETA PROTEIN[1-37]; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-39]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-41]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-43]; AMYLOID BETA PROTEIN[11-42]; AMYLOID BETA PROTEIN[2-43]; AMYLOID BETA PROTEIN[3-41]; AMYLOID BETA PROTEIN[4-40]; AMYLOID BETA PROTEIN[4-42]; AMYLOID BETA PROTEIN[5-42]; AMYLOID BETA PROTEIN[8-40]; AMYLOID BETA PROTEIN[9-40]; AMYLOID BETA PROTEIN[9-42]; DODECYL SULFATE SODIUM; FORMIC ACID; OLIGOMER; PHOSPHOPROTEIN; SODIUM CHLORIDE; TAU PROTEIN; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; ARTICLE; CADAVER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MOLECULAR WEIGHT; NEUROPATHOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN ASSEMBLY; RADIOIMMUNOPRECIPITATION; SOLUBILITY; TAUOPATHY; WESTERN BLOTTING;

EID: 84861330645     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt121     Document Type: Article

References (57)

1. Correlations of synaptic and pathological markers with cognition of the elderly. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P, Neurobiol Aging 1995 16 285 298 discussion 298-304 10.1016/0197-4580(95)00013-5 7566338
2. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P, Yen SH, Aronson MK, Neurobiol Aging 1992 13 179 189 10.1016/0197-4580(92)90027-U 1311804
3. Filling the gaps in the Ab cascade hypothesis of Alzheimer's disease. Golde TE, Dickson DW, Hutton M, Curr Alz Res 2006 3 421 430 10.2174/ 156720506779025189 (Pubitemid 46066421)
4. Revising the definition of Alzheimer's disease: a new lexicon. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Mequro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P, Lancet Neurol 2010 9 1118 1127 10.1016/S1474-4422(10) 70223-4 20934914
5. The amyloid-beta precursor protein: integrating structure with biological function. Reinhard C, Hebert SS, De Strooper B, Embo J 2005 24 3996 4006 10.1038/sj.emboj.7600860 16252002 (Pubitemid 41752869)
6. The secretases: enzymes with therapeutic potential in Alzheimer disease. De Strooper B, Vassar R, Golde T, Nat Rev Neurol 2010 6 99 107 10.1038/nrneurol.2009.218 20139999
7. The presenilin 1 C92S mutation increases abeta 42 production. Lewis PA, Perez-Tur J, Golde TE, Hardy J, Biochem Biophys Res Commun 2000 277 261 263 10.1006/bbrc.2000.3646 11027672
8. The profile of soluble amyloid beta protein in cultured cell media. Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry. Wang R, Sweeney D, Gandy SE, Sisodia SS, J Biol Chem 1996 271 31894 31902 10.1074/jbc.271.50.31894 8943233 (Pubitemid 26422211)
9. The role of A beta 42 in Alzheimer's disease. Younkin SG, J Physiol Paris 1998 92 289 292 10.1016/S0928-4257(98)80035-1 9789825 (Pubitemid 29050951)
10. Potent amyloidogenicity and pathogenicity of Abeta43. Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, Matsuba Y, Yamada K, Nilsson P, Takano J, Nishimura M, Iwata N, Van Broeckhoven C, Ihara Y, Saido TC, Nat Neurosci 2011 14 1023 1032 10.1038/nn.2858 21725313
11. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Lewczuk P, Esselmann H, Groemer TW, Bibl M, Maler JM, Steinacker P, Otto M, Kornhuber J, Wiltfang J, Biol Psychiatry 2004 55 524 530 10.1016/j.biopsych.2003.10.014 15023581 (Pubitemid 38338541)
12. The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M, Maler JM, Ruther E, Kornhuber J, Wiltfang J, Rapid Commun Mass Spectrom 2003 17 1291 1296 10.1002/rcm.1048 12811752 (Pubitemid 36750013)
13. Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, Schleuder D, Jahn H, Ruther E, Kornhuber J, Annaert W, De Strooper B, Saftiq P, J Biol Chem 2001 276 42645 42657 10.1074/jbc.M102790200 11526104
14. Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome. Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, Glabe C, Neurobiol Dis 2001 8 792 806 10.1006/nbdi.2001.0431 11592849 (Pubitemid 33055596)
15. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P, Nordstedt C, Terenius L, Proc Natl Acad Sci USA 1994 91 8378 8382 10.1073/pnas.91.18.8378 8078890 (Pubitemid 24273667)
16. The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Kuo YM, Beach TG, Sue LI, Scott S, Layne KJ, Kokjohn TA, Kalback WM, Luehrs DC, Vishnivetskaya TA, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Weller RO, Roher AE, Mol Med 2001 7 609 618 11778650 (Pubitemid 34175289)
17. Selectively increased oxidative modifications mapped to detergent-insoluble forms of Abeta and beta-III tubulin in Alzheimer's disease. Boutte AM, Woltjer RL, Zimmerman LJ, Stamer SL, Montine KS, Manno MV, Cimino PJ, Liebler DC, Montine TJ, FASEB J 2006 20 1473 1483 10.1096/fj.06-5920com 16816122 (Pubitemid 44943855)
18. The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. He W, Barrow CJ, Biochemistry 1999 38 10871 10877 10.1021/bi990563r 10451383 (Pubitemid 29404419)
19. Pyroglutamate-modified amyloid beta-peptides - AbetaN3(pE) - strongly affect cultured neuron and astrocyte survival. Russo C, Violani E, Salis S, Venezia V, Dolcini V, Damonte G, Benatti U, D'Arrigo C, Patrone E, Carlo P, Schettini G, J Neurochem 2002 82 1480 1489 10.1046/j.1471-4159.2002.01107.x 12354296
20. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Bohm G, Demuth HU, Biochemistry 2006 45 12393 12399 10.1021/bi0612667 17029395 (Pubitemid 44583682)
21. Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA, Acta Neuropathol 2009 118 487 496 10.1007/s00401-009-0557-5 19547991
22. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Abeta deposits in hippocampus via distinct cellular mechanisms. Hartlage-Rubsamen M, Morawski M, Waniek A, Jager C, Zeitschel U, Koch B, Cynis H, Schilling S, Schliebs R, Demuth HU, Rossner S, Acta Neuropathol 2011 121 705 719 10.1007/s00401-011-0806-2 21301857
23. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Harper JD, Lansbury PT Jr, Annu Rev Biochem 1997 66 385 407 10.1146/annurev.biochem.66.1.385 9242912 (Pubitemid 27274662)
24. Kinetic theory of fibrillogenesis of amyloid beta-protein. Lomakin A, Teplow DB, Kirschner DA, Benedek GB, Proc Natl Acad Sci USA 1997 94 7942 7947 10.1073/pnas.94.15.7942 9223292 (Pubitemid 27343754)
25. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Hardy J, Selkoe DJ, Science 2002 297 353 356 10.1126/science.1072994 12130773 (Pubitemid 34790756)
26. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ, J Neurosci 1999 19 8876 8884 10516307 (Pubitemid 30226709)
27. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Klein WL, Krafft GA, Finch CE, Trends Neurosci 2001 24 219 224 10.1016/S0166-2236(00)01749-5 11250006 (Pubitemid 32204378)
28. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH, J Neurosci 2002 22 1858 1867 11880515 (Pubitemid 35386304)
29. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW, Murakami T, Matsubara E, Abe K, Ashe KH, Younkin SG, J Neurosci 2004 24 3801 3809 10.1523/JNEUROSCI.5543-03.2004 15084661 (Pubitemid 38509410)
30. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T, Neuron 2005 47 191 199 10.1016/j.neuron.2005.06.030 16039562 (Pubitemid 41019251)
31. Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Golde TE, Schneider LS, Koo EH, Neuron 2011 69 203 213 10.1016/j.neuron.2011.01.002 21262461
32. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC, Brain 2009 132 1355 1365 10.1093/brain/awp062 19339253
33. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Wang J, Dickson DW, Trojanowski JQ, Lee VM, Exp Neurol 1999 158 328 337 10.1006/exnr.1999.7085 10415140 (Pubitemid 29382824)
34. Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. Maarouf CL, Daugs ID, Kokjohn TA, Walker DG, Hunter JM, Kruchowsky JC, Woltjer R, Kaye J, Castano EM, Sabbagh MN, Beach TG, Roher AE, PLoS One 2011 6 27291 10.1371/journal.pone.0027291 22087282
35. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ, Nat Med 2008 14 837 842 10.1038/nm1782 18568035
36. Saido TC, Yokota M, Tani E, Kawashima S, Alzheimer's Disease: Biology, Diagnosis and Therapeutics New York: Wiley 1997 22627700
37. Plaque-associated neuronal proteins: a recurrent motif in neuritic amyloid deposits throughout diverse cortical areas of the Alzheimer's disease brain. Schmidt ML, DiDario AG, Otvos L Jr, Hoshi N, Kant JA, Lee VM, Trojanowski JQ, Exp Neurol 1994 130 311 322 10.1006/exnr.1994.1209 7867760
38. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG, J Neurosci 2001 21 372 381 11160418 (Pubitemid 32107428)
39. BRI2 (ITM2b) inhibits Abeta deposition in vivo. Kim J, Miller VM, Levites Y, West KJ, Zwizinski CW, Moore BD, Troendle FJ, Bann M, Verbeeck C, Price RW, Smithson L, Sonoda L, Wagg K, Rangachari V, Zou F, Younkin SG, Graff-Radford N, Dickson D, Rosenberry T, Golde TE, J Neurosci 2008 28 6030 6036 10.1523/JNEUROSCI.0891-08.2008 18524908
40. Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide 1-42. Butterfield DA, Kanski J, Peptides 2002 23 1299 1309 10.1016/S0196-9781(02)00066-9 12128086 (Pubitemid 34786708)
41. Methionine 35 oxidation reduces fibril assembly of the amyloid abeta-(1-42) peptide of Alzheimer's disease. Hou L, Kang I, Marchant RE, Zagorski MG, J Biol Chem 2002 277 40173 40176 10.1074/jbc.C200338200 12198111 (Pubitemid 35215584)
42. A molecular switch in amyloid assembly: Met35 and amyloid beta-protein oligomerization. Bitan G, Tarus B, Vollers SS, Lashuel HA, Condron MM, Straub JE, Teplow DB, J Am Chem Soc 2003 125 15359 15365 10.1021/ja0349296 14664580 (Pubitemid 37532178)
43. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Cynis H, Scheel E, Saido TC, Schilling S, Demuth HU, Biochemistry 2008 47 7405 7413 10.1021/bi800250p 18570439 (Pubitemid 351991019)
44. Toxicity of pyroglutaminated amyloid beta-peptides 3(pE)-40 and -42 is similar to that of A beta1-40 and -42. Tekirian TL, Yang AY, Glabe C, Geddes JW, J Neurochem 1999 73 1584 1589 10501204 (Pubitemid 29440160)
45. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Harigaya Y, Saido TC, Eckman CB, Prada CM, Shoji M, Younkin SG, Biochem Biophys Res Commun 2000 276 422 427 10.1006/bbrc.2000.3490 11027491
46. Beta-amyloid peptide variants in brains and cerebrospinal fluid from amyloid precursor protein (APP) transgenic mice: comparison with human Alzheimer amyloid. Schieb H, Kratzin H, Jahn O, Mobius W, Rabe S, Staufenbiel M, Wiltfang J, Klafki HW, J Biol Chem 2011 286 33747 33758 10.1074/jbc.M111.246561 21795681
47. Pyroglutamate amyloid-beta (Abeta): a hatchet man in Alzheimer disease. Jawhar S, Wirths O, Bayer TA, J Biol Chem 2011 286 38825 38832 10.1074/jbc.R111.288308 21965666
48. Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. Jawhar S, Wirths O, Schilling S, Graubner S, Demuth HU, Bayer TA, J Biol Chem 2011 286 4454 4460 10.1074/jbc.M110.185819 21148560
49. Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Abeta is induced by pyroglutamate-Abeta formation. Alexandru A, Jagla W, Graubner S, Becker A, Bauscher C, Kohlmann S, Sedlmeier R, Raber KA, Cynis H, Ronicke R, Reymann KG, Petrasch-Parwez E, Hartlage-Rubsamen M, Waniek A, Rossner S, Schilling S, Osmand AP, Demuth HU, von Horsten S, J Neurosci 2011 31 12790 12801 10.1523/JNEUROSCI.1794-11.2011 21900558
50. Pyroglutamate A(beta) aggravates behavioral deficits in 5XFAD mice. Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth HU, Blennow K, Wirths O, Bayer TA, J Biol Chem 2012 287 8154 8162 10.1074/jbc.M111.308601 22267726
51. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ, Nature 2002 416 535 539 10.1038/416535a 11932745 (Pubitemid 34288854)
52. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ, J Physiol 2006 572 477 492 10.1113/jphysiol.2005.103754 16469784
53. A specific amyloid-beta protein assembly in the brain impairs memory. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH, Nature 2006 440 352 357 10.1038/nature04533 16541076
54. Alzheimer's disease: genetic studies and transgenic models. Price DL, Tanzi RE, Borchelt DR, Sisodia SS, Annu Rev Genet 1998 32 461 493 10.1146/annurev.genet.32.1.461 9928488 (Pubitemid 29045321)
55. Probing the biology of Alzheimer's disease in mice. Ashe KH, Zahs KR, Neuron 2010 66 631 645 10.1016/j.neuron.2010.04.031 20547123
56. Neuropathology of older persons without cognitive impairment from two community-based studies. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS, Neurology 2006 66 1837 1844 10.1212/01.wnl.0000219668.47116.e6 16801647 (Pubitemid 44049813)
57. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD, JAMA 2000 283 1571 1577 10.1001/jama.283.12.1571 10735393 (Pubitemid 30161512)